高血压患者人巨细胞病毒感染率及其血浆中和抗体水平分析

目的 对高血压患者人巨细胞病毒（HCMV）感染率及其血浆中和抗体水平展开研究分析,研究高血压与人巨细胞病毒感染的相关性.方法 随机选取2011年12月-2013年12月期间接收治疗的50例高血压患者血标本作为观察组,同时选取50例健康体检人员的血标本作为对照组.对两组标本人巨细胞病毒特异性中和抗体、人巨细胞病毒特异性IgG和IgM、人巨细胞病毒特异性UL93 DNA进行检测.结果 观察组HCMV UL93 DNA的阳性率为72.0％,HCMV IgG阳性率为70.0％,HCMV IgM阳性率为4.0％;对照组HCMV UL93 DNA阳性率为54.0％,HCMV IgG阳性率为52.0％,HCMV IgM阳性率为2.0％;观察组HCMV UL93 DNA阳性率、HCMV IgG阳性率显著高于对照组,数据差异具有统计学意义（P＜0.05）;两组HCMV IgM阳性率数据对比差异无统计学意义（P＞0.05）.结论 高血压患者人巨细胞病毒感染率显著高于健康对照组,但特异性中和抗体水平较健康对照组显著下降,即高血压患者的人巨细胞病毒感染体液免疫状态不足,高血压与人巨细胞病毒感染显著相关.     

542例O型血孕妇血清中IgG抗A(B)抗体效价结果分析

目的了解O型血孕妇血清中IgG抗A(B)抗体效价阳性率。方法采用间接抗人球法检测IgG抗A(B)抗体效价。结果检测效价在1∶64以上者达16.7%,且O-A组O-B组阳性率无显著性差异(P>0.05,χ2=1.72)。结论检测孕妇血清中IgG类抗体效价,≥1∶64者及时治疗,可预防和减低新生儿溶血病的发生。     

类风湿关节炎患者CMV、B19和HCV抗体的检测及临床意义

目的:检测巨细胞病毒(CMV)IgG和IgM抗体、细小病毒B19 IgG和IgM抗体及丙型肝炎病毒(HCV)抗体在中国南方类风湿关节炎(RA)患者外周血中的表达,探讨CMV、B19、HCV在RA中的作用。方法:采用酶联免疫吸附试验(ELISA)法检测CMV-IgG和CMV-IgM抗体,B19-IgG和B19-IgM抗体以及HCV抗体;CMV-IgM抗体阳性者利用实时定量PCR法检测外周血单个核细胞中的CMV载量;B19-IgM抗体阳性者利用实时定量PCR法检测血清中的B19载量。同时分析这些病毒抗体与RA患者的实验室活动指标如抗环瓜氨酸肽(CCP)抗体、类风湿因子(RF)、红细胞沉降率(ESR)的相关性。结果:70例RA患者中,69例为CMV-IgG抗体阳性(98.57%),7例CMV-IgM抗体阳性(10.00%),49例B19-IgG抗体阳性(70.00%),16例B19-IgM抗体阳性(22.86%),无一例HCV抗体阳性;92例健康对照者中91例CMV-IgG抗体阳性(98.91%),1例CMV-IgM抗体阳性(1.10%),42例B19-IgG抗体阳性(45.65%),19例B19-IgM抗体阳性(20.65%),仅1例HCV抗体阳性;RA患者CMV-IgM抗体阳性率明显高于对照组(P<0.05),CMV-IgM抗体阳性RA患者外周血单个核细胞未检测到CMV载量;RA患者B19-IgG抗体阳性率明显高于对照组(P<0.01),而两组间B19-IgM抗体阳性率无差别(P>0.05),B19-IgM抗体阳性RA患者血清中未检测到B19载量;CMV-IgM抗体阳性、B19-IgG抗体阳性与抗CCP抗体、RF、ESR等RA活动性指标不相关。结论:中国南方人群普遍感染CMV,但CMV重新激活与RA有关;B19感染在RA患者中有更高的流行率;HCV在中国南方人群感染率低。     

Alzheimer患者血清中抗Aβ42自身抗体的纯化及鉴定

目的:纯化并鉴定阿尔茨海默病(AD)患者血清中抗Aβ2自身抗体.方法:选择AD患者做为研究对象,采集血清标本,测定抗体含量,用饱和硫酸铵沉淀血清得到IgG粗品,Aβ42免疫亲和柱层析对粗品IgG进一步分离纯化,采用PAGE电泳和Western blot方法鉴定IgG纯度和免疫活性.结果:用CNBr活化Sephrose 4B柱层析纯化出较高纯度的抗Aβ42自身抗体,纯度可达到90%.结论:CNBr活化Sephrose4B层析柱可有效地从人血清中纯化出较高纯度的抗Aβ42自身抗体,便于对自身抗体进一步研究,为AD的免疫治疗提供更多的信息.     

血清IgG4、CA19-9 水平对IgG4 相关性胆管炎的诊断及鉴别诊断价值

目的:探讨血清IgG4、CA19-9 及自身抗体对IgG4 相关性胆管炎(IgG4-SC)的诊断及鉴别价值。方法:选取41例IgG4-SC 患者、162 例非IgG4-SC 患者及40 例健康对照血清样本,采用免疫比浊法和直接化学发光法检测IgG4 和CA19-9水平、采用间接免疫荧光法检测抗核抗体(ANA)、抗中性粒细胞胞浆抗体(ANCA)、抗平滑肌抗体(SMA)和抗线粒体抗体(AMA),并进行结果统计分析。结果: IgG4-SC 患者的ANA、ANCA、SMA 和AMA 阳性率分别为41.46%、7.32%、0 和2.44%。其中,ANA 阳性率与正常对照组、ANCA 阳性率与原发性硬化性胆管炎(PSC)组、SMA 和AMA 阳性率与非IgG4-SC组均存在差异,且具有非常显著统计学意义(P<0.01)。于血清IgG4(n =36/41)和CA19-9(n =21/41)升高情况与正常对照组相比,差异具有统计学意义(P<0.01);其ROC 曲线下面积(AUC)分别为0.979 和0.646,P<0.05。结论:血清IgG4 和CA19-9水平的高表达和自身抗体检测,对于IgG4-SC 的鉴别诊断具有准确性和重要临床价值。     

大连地区O型血型孕妇产前ABO系统IgG抗体效价筛查

目的 检测O型孕妇ABO血型IgG抗体效价方法 用微柱凝胶法抗人球蛋白试验测定O型孕妇IgG抗体效价结果 266例O型孕妇总阳性率80.5%(214∕266).在O-A组中,其中IgG抗A效价＞64者占68.5%(63∕92).在O-B组中,IgG抗B效价＞64者占65.9%(58∕88),在O-AB组中,IgG抗A、抗B效价＞64者均占74.4%(32∕43),各组均有发生新生儿溶血病的可能讨论通过微柱凝胶免疫检测法孕妇血清血型抗体IgG效价有助于诊断新生儿溶血病,指导临床干预措施.     

抗ABCA1自身抗体在SLE患者动脉粥样硬化发病机制中的意义

检测系统性红斑狼疮(SLE)患者血清中抗三磷酸腺苷结合盒转运子(ABCA1)抗体及探讨其致SLE早发动脉粥样硬化(AS)的机制。采用免疫印迹法检测75份SLE患者血清中抗ABCA1自身抗体。75份性别年龄匹配正常人血清为对照。观察抗ABCA1抗体阳性患者血清IgG对细胞胆固醇流出的影响。结果显示,SLE患者血清中存在抗ABCA1抗体,阳性率为29.3%,正常人中无一阳性(P<0.05)。SLE有斑块组的抗ABCA1抗体阳性率高于SLE无斑块组(43.8%和16.3%,P<0.05)。纯化的抗ABCA1抗体阳性SLE患者IgG体外可抑制THP-1细胞内胆固醇的流出,抑制率最高可达28.7%,正常人IgG抑制率相比有显著性差异。实验表明,SLE患者血清中抗ABCA1抗体阳性率明显高于正常人,且纯化的抗AB-CA1抗体阳性患者IgG在体外能抑制细胞内胆固醇的流出,从而促进SLE患者早发动脉粥样硬化的发生。     

脑炎与人微小病毒B19感染-附1例PCR检测结果分析

我室用多聚酶链反应技术及ELISA法对1例临床拟诊为脑炎志儿的血清及脑脊液分别作了人微小病毒B19-DNA及该病毒特异性IgM、IgG抗体检测。其结果血清及脑脊液B19特异性IgM抗体均为强阳性；血清B19特异性IgG抗体阴性．脑脊液B19特异性IgG抗体强阳性；血清中检出B19-DNA。在国内首次提示人微小病毒B19感染与脑炎的发生有关。     

无偿献血人群戊型肝炎病毒感染情况调查

目的调查绍兴市街头无偿献血者戊型肝炎病毒感染情况。方法3701例无偿献血者标本采用ELISA方法检测抗-HEV IgG和抗-HEV IgM,RT-PCR检测抗-HEV IgM阳性血清HEV RNA。结果本市无偿献血者抗-HEV IgG阳性率为29.91%(1107/3701);抗-HEVIgM阳性率为1.35%(50/3701);HEV RNA阳性6例,检出率为0.16%(6/3701),均为HEV基因1型;各季节抗-HEV IgG和抗-HEV IgM的阳性检出率无显著差异。结论加强对献血者感染HEV情况的检测和研究,对保证用血安全,完善安全输血的保障体系有切实的意义。     

人抗Aβ42自身抗体的纯化及鉴定

目的纯化并鉴定正常人血清中抗Aβ42自身抗体。方法采集正常人血清标本,测定抗体含量,用饱和硫酸铵沉淀血清得到IgG粗品,用CNBr Sephrose 4B层析柱对粗品IgG进一步纯化,采用PAGE电泳和Westernblot方法鉴定IgG纯度和免疫活性。结果用CNBr活化Sephrose4B柱可纯化出较高纯度的抗AB42自身抗体,纯度可达到90％。结论CNBr活化Sephrose4B层析柱可有效地从人血清中纯化出较高纯度的抗A％自身抗体,便于对自身抗体进一步研究,为AD的免疫治疗提供更多的信息。     

A population-based epidemiological survey of human parvovirus B19 infection: a project of the Kyushu and Okinawa Population Study (KOPS)

Human parvovirus B19 infection occurs by droplet nuclei through the respiratory tract and causes a wide range of diseases. It can be transmitted through blood transfusion from asymptomatic blood donors. This study was done to investigate the parvovirus B19 infection rate of a group of healthy Japanese residents. Of 2,081 blood samples tested, 15 (0.72 %) were positive for parvovirus B19 IgM, 1,412 (67.9 %) for B19 virus IgG, and 4 (0.2 %) for parvovirus B19 DNA. About half of all women of childbearing age were susceptible to parvovirus B19 infection. No relationship was found between the frequency of symptoms and the prevalence of parvovirus B19 IgG and IgM, suggesting that there are asymptomatic carriers in the healthy Japanese population. There is a risk of parvovirus B19 infection by blood transfusion from asymptomatic donors and that pregnant women are at high risk for parvovirus B19 infection.     

Evidence for persistence of human parvovirus B19 DNA in bone marrow

A nested polymerase chain reaction assay (nPCR) was used to investigate the potential of human parvovirus B19 DNA to persist in blood or bone marrow samples obtained either from blood donors or cadaveric bone donors or from patients presenting with clinical signs of parvovirus B19 infection. The presence of parvovirus B19 specific antibody in blood was tested by enzyme immunoassay (EIA). B19 virus genome was not detected in any blood sample of 115 blood donors, of whom 92 (80%) had anti-B19 IgG antibody only as an indication of past infection. In contrast, B19 virus DNA was detected in the bone marrow of 4 out of 45 bone donors. Each one of the serum samples available for 3 of these 4 individuals contained anti-B19 IgG antibody. Among 84 patients with clinical manifestations of parvovirus B19 infection, 17 (20%) had B19 virus DNA in bone marrow. Eight of the latter patients had anti-B19 IgG antibody in their blood but neither anti-B19 IgM nor B19 virus DNA. These data document the ability of parvovirus B19 DNA to persist in the bone marrow of asymptomatic individuals and patients with parvovirus B19 infection suspected on clinical grounds. J. Med. Virol. 53:229–232, 1997. © 1997 Wiley-Liss, Inc.     

Presence and significance of human parvovirus B19 DNA in synovial membranes and bone marrow from patients with arthritis of unknown origin

Acute rheumatologic symptoms are frequently associated with human parvovirus B19 (B19) infections. A nested PCR (nPCR) assay was used to test for the presence of parvovirus B19 DNA in synovial fluid and/or synovial membrane specimens obtained from a total of 90 patients with arthritis of unknown origin. Whereas only one out of 73 synovial fluid samples were found positive, 15 (16.7%) out of 90 patients had parvovirus B19 DNA in the synovium. B19 virus DNA was detected in nine bone marrow aspirates subsequently obtained from these 15 patients (60%). Whereas each one of the 15 corresponding blood samples contained anti-B19 IgG antibody, none contained anti-B19 IgM antibody and only one was positive for B19 virus DNA. The blood and synovial fluid samples that contained B19 virus DNA were obtained from the same patient, who also had B19 DNA in synovium and bone marrow. For one patient, two distinct synovial membrane specimens collected 10 months apart tested positive for B19 virus DNA. Parvovirus B19 DNA was also detected in synovial tissue of one out of nine nonarthritic patients serving as control group, who also had anti-B19 IgG circulating antibody. These data illustrate that human parvovirus B19 may persist in bone marrow and synovial tissues of patients with arthritis of unknown origin. In contrast, persistence of B19 virus DNA in synovial fluid is rare. The significance of parvovirus B19 DNA in synovium of healthy patients has to be established. J. Med. Virol. 56:199–204, 1998. © 1998 Wiley-Liss, Inc.     

The prevalence and persistence of human parvovirus B19 infection in thalassemic patients

Human parvovirus B19 infection was studied in 60 thalassemic patients in Thailand. Seroprevalence, persistence of parvovirus B19 and their genotypes were identified in blood samples. Prevalence of anti-parvovirus B19 IgG and DNA found in thalassemic patients were 38% and 13%, respectively. Anti-parvovirus B19 IgM could be detected in 4% of these positive anti-parvovirus B19 IgG patients. The seroprevalence and parvovirus B19 DNA in patients with a history of blood transfusion were not significantly higher than those without such a history (44% vs. 34% and 20% vs. 9%, respectively). Phylogenetic analysis of NS1 nucleotide sequences of three parvovirus B19 samples revealed that they were parvovirus B19 genotype 1. They showed low genetic diversity from prototype (Au) strain. We concluded that acute and chronic persistent parvovirus B19 infection were found in the thalassemic Thai patients. Chronic persistence of parvovirus B19 infection might play important clinical role in thalassemic patients because of the high prevalence of parvovirus B19 DNA. Blood transfusion had no significant influence to increase the prevalence of parvovirus B19 infection in thalassemic patients.     

Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates

A group of 27 first infused haemophiliacs was studied for association between heat-treated clotting factor concentrates and transmission of human parvovirus B19. The prevalence rate of B19 antibody, detected by the Immunoelectroosmophoresis (IEOP) reaction, was 55.5% in this group of first infused subjects, significantly higher than the 29.3% of the control group of 58 healthy blood donors but lower than the 93.3% of antibody positive subjects in a group of 30 haemophiliacs multitreated with unheated products. Five of 17 B19 antibody negative patients produced human parvovirus IgM, detectable by radioimmunoassay, after the first treatment with heated concentrates; two of them developed viraemia 6 and 10 days, respectively, after the first infusion dose. These results lead to the conclusion that human parvovirus is transmissible by blood derivatives even when they have been exposed to steam- or dry-heat treatment.     

Investigation on the Maternal-Infantile Infection with Human Parvovirus B19

With the investigations on pregnant women and newbornsinfected withToxoplasma, rubella virus, cytomegalovirus,herpes simplex virus (TORCH), it was found that humanparvovirus B19 (B19 virus), which belongs to the familyParvoviridae and the genus Erythrovir…     

SARS COV-2- IgG antibodies in blood donors in pandemic – A game changer for policy makers

BackgroundA novel beta coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has been identified as the causative pathogen for the present pandemic. The objective of the study was to measure the levels of IgG antibodies targeting the SARS-CoV-2 during the peak period of the COVID-19 pandemic in Odisha State, India to know the magnitude of SARS-CoV-2 exposure, the prevalence of herd immunity in the population, the distribution of IgG-positive cases examined according to ABO blood groups and the number of blood donors with higher neutralizing IgG antibody titre who later on were converted into Plasma Donors donating Convalescent Plasma (CP).MethodThis observational prospective study was conducted for a duration of three months on 1032 number of Blood donors consisting of 1025 number of males and 07 number of females. The samples of donors were subjected to Electro- chemiluminescence immunoassay (ECLIA) to detect SARS-CoV-2 IgG antibodies.ResultOut of 1032 Donors, 370(35.9%) were SARS-COV-2 IgG positive which included 303 donors (29.36%) with neutralizing antibody titre of SARS-COV2 IgG antibodies above 1:80. SARS-COV-2 IgG positive cases consisted of 367(35.8%) male and 3(42.9%) female donors. The number of IgG positive cases were highest in 21–40 years’ age group i.e. 323 out of 869(37.2%). In terms of Blood group, 145(42.4%) out of 342 were from B RhD positive group. Out of 22 donors who were positive with COVID 19 in the past with neutralizing IgG antibody titre more than 1:80, 6(27.3%) persons came for voluntary convalescent plasma(CP) donation.ConclusionA high prevalence of SARS-CoV-2 antibodies was detected among blood donors which indicated a high level of exposure to the virus within the population and development of innate immunity against the virus. Policy makers can add the protocol of antibody testing in the screening of blood donors to enhance the number of Plasma Donation cases for the treatment of serious COVID patients.     

Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy

An increased human parvovirus B19 infection rate has been observed in immunocompromised hosts. In this study, we sought to determine the prevalence of parvovirus B19 infection in adult cancer patients receiving multiple courses of systemic chemotherapy. From March 1999 through April 2000, 59 men and 68 women, with a median age of 49 (18 to 79) years, were enrolled in this study. They had received an average of 7.1 (4 to 32) courses of systemic chemotherapy. The median duration from the date of starting chemotherapy to the date of blood sampling was 11 (4 to 88) months. Serum B19 immunoglobulin G (IgG) and IgM levels were examined by an enzyme-linked immunosorbent assay, and B19 DNA was examined by a nested PCR. A group of 400 healthy blood donors served as the control group. The overall prevalences of anti-B19 IgG in adult cancer patients and healthy blood donors were 61.4 and 25.0%, respectively (P < 0.01). Anti-B19 IgM and B19 DNA were not detectable in these anti-B19 IgG-seropositive individuals. A further age-stratified comparison revealed that only patients younger than 40 years had a significantly higher anti-B19 IgG seropositivity rate than the controls (19 of 39 versus 53 of 310; P < 0.001). The increased prevalence of B19 infection in these 39 adult patients younger than 40 years might be clinically significant, since unexplained anemia, a common sequela of B19 infection, was detected in 3 of 20 seronegative patients (15.0%) and in 12 of 19 seropositive patients (63.2%) (P < 0.005). The results of this study suggest that adult patients younger than 40 years and receiving multiple courses of systemic chemotherapy may have a significantly increased risk of B19 infection. Prospective studies to define the time course and clinical consequence of B19 infection in this group of patients are needed.     

Prevalence and partial sequence analysis of human T cell lymphotropic virus type I in China

A total of 145,293 serum samples were collected from volunteer blood donors in 13 provinces of China and tested for anti-HTLV antibody using an ELISA licensed in China. Thirty were positive for anti-HTLV by ELISA and 19 of those 30 samples were confirmed positive using a supplemental immunoblot assay. Anti-HTLV-I was detected only in samples from Fujian province (a Southern province) where the positivity rate was approximately 0.05%. The region encoding gp46 from 5 of the 19 antibody positive samples was amplified and sequenced. Sequence analysis indicated that these isolates belong to HTLV-I genotype A. These data suggest that HTLV-I is not endemic throughout China and the virus may be restricted to a particular region.     

浙南地区无偿献血者戊型肝炎亚临床感染及病毒血症情况调查

目的 调查浙江南部地区戊型肝炎的感染情况.方法 对2008年2-10月间浙江省温州市中心血站的无偿献血者进行整群抽样,检测抗HEV IgG以及IgM抗体,并对抗HEV IgM阳性的标本进行RT-PCR检测,经测序后分析其基因型及序列同源性.结果 3044例无偿献血者中,HEVIsG阳性率为33.28%,随着年龄的升高IgG阳性率也有一定的提高,从20岁组的21.16%升高到40岁以上组的50.36%;IgM阳性率0.92%,以31～40岁年龄段感染率最高,为1.90%.通过对IgG和lgM各自阴阳性标本群的分析发现其与献血者的年龄、性别以及血型并无显著相关性.对28例HEV IgM阳性标本进行PCR检测共发现3例核酸阳性,总体阳性率约为10%,其中2例为基因4型,1例为基因1型感染.结论 浙南地区的无偿献血者中存在一定比率的HEV病毒携带者.